Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

Inclusion Criteria: * Age 18 years of older * Angiographically confirmed multivessel CAD \[critical (\>70%) lesions in at least two major epicardial vessels and in at least two separate coronary artery territories (LAD, LCX, RCA)\] and amenable to either PCI or CABG. * Indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia * Geographically accessible and willing to come in for required study visits * Signed informed consent. Exclusion Criteria: * Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema) at the time of enrollment. * Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stent). * In-stent restenosis of a target vessel * Prior CABG surgery * Prior PCI with stent implantation within 1 year * Two or more chronic total occlusions in major coronary territories * Acute ST-elevation MI(Q-wave) within 72 hours prior to enrollment requiring revascularization * Abnormal creatine kinase (CK \> 2x normal) and/or abnormal CK-MB levels and/or elevated Troponin levels at time of randomization * Previous stroke within 6 months or patients with stroke at more than 6 months with significant residual neurologic involvement, as reflected in a Rankin Score \> 1 * Dementia with a Mini Mental Status Examination (MMSE) score of ≤ 20 * Extra-cardiac illness that is expected to limit survival to less than 2 years; e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease. * Prior history of significant bleeding (within the previous 6 months) that might be expected to occur during CABG or PCI/DES related anticoagulation. * Contraindication either CABG or PCI/DES because of a coexisting clinical condition * Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis * Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine * Suspected pregnancy. A pregnancy test (urine or serum) will be administered prerandomization to all women not clearly menopausal * Concurrent enrollment in another clinical trial